Sanofi Reports Phase 2 Data for Lapatinib in Gaucher disease

Sanofi today announced Phase 2 results for Lapatinib in patients with Gaucher disease. The study demonstrated that Lapatinib provides durable benefit over long-term follow-up compared to standard of care or placebo. These results provide important insights into the treatment of Gaucher disease and support the continued development of Lapatinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Lapatinib was consistent with previous observations, with no new safety signals identified.